PDF(Pubmed)
Abstract：
Policies promoting price transparency may be an important approach to control medicine prices and achieve better access to medicines. As part of a wider review, we aimed to systematically determine whether policies promoting price transparency are effective in managing the prices of pharmaceutical products. We searched for studies published between January 1, 2004 and October 10, 2019, comparing policies promoting price transparency against other interventions or a counterfactual. Eligible study designs included randomized trials, and non-randomized or quasi-experimental studies such as interrupted time-series (ITS), repeated measures (RM), and controlled before-after studies. Studies were eligible if they included at least one of the following outcomes: price (or expenditure as a proxy for price and volume), volume, availability or affordability of pharmaceutical products. The quality of the evidence was assessed using the GRADE methodology. A total of 32011 records were retrieved, two of which were eligible for inclusion. Although based on evidence from a single study, public disclosure of medicine prices may be effective in reducing prices of medicines short-term, with benefits possibly sustained long-term. Evidence on the impact of a cost-feedback approach to prescribers was inconclusive. No evidence was found for impact on the outcomes volume, availability or affordability. The overall lack of evidence on policies promoting price transparency is a clear call for further research.
摘要：
促进价格透明度的政策可能是控制药品价格和更好地获得药品的重要方法。作为更广泛审查的一部分，我们旨在系统地确定促进价格透明度的政策在管理药品价格方面是否有效。我们搜索了2004年1月1日至2019年10月10日之间发表的研究，比较了促进价格透明度的政策与其他干预措施或反事实。符合条件的研究设计包括随机试验，以及非随机或准实验研究，如中断时间序列(ITS)，重复措施(RM)，控制前后研究。如果研究至少包括以下结果之一，则符合资格：价格（或支出作为价格和数量的代理），volume,药品的可获得性或可负担性。使用GRADE方法评估证据的质量。共检索到32011条记录，其中两人有资格入选。尽管根据一项研究的证据，药品价格的公开披露可能会在短期内有效降低药品价格，有可能长期持续的好处。关于成本反馈方法对处方者的影响的证据尚无定论。没有发现对结果量的影响的证据，可用性或负担能力。总体上缺乏有关促进价格透明度的政策的证据，这显然需要进一步研究。
